MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-08-2024
G1 Therapeutics ROA Ratio 2011-2026 | GTHX
Annual ROA Ratio G1 Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -39.47 | -78.5 | -58.38 | -43.43 | -42.99 | -22.97 | -57.16 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -22.97 | -78.5 | -48.99 |
Quarterly ROA Ratio G1 Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -42.91 | -31.48 | -24.83 | -40.0 | -41.49 | -69.92 | -60.25 | -76.0 | -55.73 | -69.98 | -56.0 | -51.35 | -39.01 | -38.42 | -43.43 | -44.78 | -51.03 | -48.15 | -42.99 | -37.04 | -31.04 | -25.88 | -22.97 | -32.63 | -42.1 | -50.92 | -57.16 | -62.59 | -61.36 | -62.22 | -50.48 | -28.91 | -15.31 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -15.31 | -76.0 | -45.71 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B |  USA |
 |
Aptorum Group Limited
APM
|
-7.29 | $ 0.89 | - | $ 6.54 M | China |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
19.07 | $ 22.2 | - | $ 3.68 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Edesa Biotech
EDSA
|
-161.77 | $ 15.9 | - | $ 50.8 M | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Evogene Ltd.
EVGN
|
-39.9 | $ 0.76 | - | $ 27.9 M |  Israel |
 |
Exelixis
EXEL
|
27.51 | $ 44.69 | - | $ 12.1 B | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Galapagos NV
GLPG
|
-1.99 | $ 27.86 | - | $ 2.69 B |  Belgium |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Grifols, S.A.
GRFS
|
1.38 | $ 7.91 | - | $ 6.83 B |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
12.48 | $ 31.05 | - | $ 1.79 B | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
ImmuCell Corporation
ICCC
|
-2.45 | $ 8.44 | - | $ 76.2 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1008.51 | - | -2.5 % | $ 5.88 M | USA |
 |
BioNTech SE
BNTX
|
65.02 | $ 101.57 | - | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Immuron Limited
IMRN
|
-11.48 | $ 0.81 | 0.3 % | $ 9.47 M |  Australia |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Incyte Corporation
INCY
|
18.49 | $ 99.1 | - | $ 19.3 B | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
InMed Pharmaceuticals
INM
|
-56.34 | $ 0.7 | - | $ 1.71 M | Canada |
 |
INmune Bio
INMB
|
-141.98 | $ 1.33 | - | $ 32.9 M | USA |
 |
Innoviva
INVA
|
16.58 | $ 23.05 | - | $ 1.55 B | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Innate Pharma S.A.
IPHA
|
-19.74 | $ 1.48 | -0.67 % | $ 235 M | France |
 |
Jaguar Health
JAGX
|
-139.8 | $ 7.88 | - | $ 18.4 M | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-76.23 | - | - | $ 28.6 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-32.66 | $ 26.67 | - | $ 1.44 B | Britain |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
Kamada Ltd.
KMDA
|
-0.7 | $ 8.11 | - | $ 260 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 2.98 | - | $ 4.91 M | Israel |
 |
Krystal Biotech
KRYS
|
15.36 | $ 259.95 | - | $ 7.52 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-70.51 | $ 12.42 | - | $ 1.65 B | Australia |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
-0.43 | $ 224.86 | - | $ 4.11 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-150.49 | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Liquidia Corporation
LQDA
|
-21.02 | $ 38.15 | - | $ 3.28 B | USA |
 |
Applied Therapeutics
APLT
|
-218.41 | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aquestive Therapeutics
AQST
|
-52.23 | $ 4.05 | - | $ 433 M | USA |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |